Evidence map›Paper›PMID 21191009›Full record

ArticleJournal of virology2011

Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Anita Changela, Xueling Wu, Yongping Yang, Baoshan Zhang, Jiang Zhu, Glenn A Nardone, Sijy O'Dell, Marie Pancera, Miroslaw K Gorny, Sanjay Phogat and 5 more

Abstract read
In one paragraph

Article in Journal of virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Germline-targeting immunogens.Immunological reviews · 2017
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Anita ChangelaVaccine Research Center, NIAID/NIH, 40 Convent Drive, Building 40, Room 4508, Bethesda, MD 20892-3027, USA.
Xueling Wu
Yongping Yang
Baoshan Zhang
Jiang Zhu
Glenn A Nardone
Sijy O'Dell
Marie Pancera
Miroslaw K Gorny
Sanjay Phogat
James E Robinson
Leonidas Stamatatos
Susan Zolla-Pazner
John R Mascola
Peter D Kwong
National Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USCenter for Infectious Disease Research · USInternational AIDS Vaccine Initiative · USNew York University · USTulane University · USVeterans Health Administration · US

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Grace C. John-Stewart · 1988 to 2026
$104.9M
Neutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6M
VIROLOGY COREP30AI027742 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZOLLA-PAZNER, SUSAN B · 1989 to 2010
$19.4M
Isolation of Monoclonal Antiobodies Against HIVZIAAI005095 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DORIA-ROSE, NICOLE · 2009 to 2025
$14.5M
Determination of the Neutralization Specificity in Broadly Neutralizing HIV SeraZIAAI005089 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MASCOLA, JOHN · 2009 to 2018
$9.6M
Measurement of HIV Neutralization Using Quantitative AssaysZIAAI005010 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MASCOLA, JOHN · 2009 to 2018
$7.6M
IMMUNOLOGIC RELATEDNESS AMONG AND BETWEEN HIV-1 SUBTYPESR01AI036085 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZOLLA-PAZNER, SUSAN B · 1994 to 2008
$5.3M
Intramural NIH HHSNIAID NIH HHS AI 27742NIAID NIH HHS AI36085NIAID NIH HHS P30 AI027742NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI036085
6 · The paper itself

Abstract

Monoclonal antibody 2909 belongs to a class of potently neutralizing antibodies that recognize quaternary epitopes on HIV-1. Some members of this class, such as 2909, are strain specific, while others, such as antibody PG16, are broadly neutralizing; all, however, recognize a region on the gp120 envelope glycoprotein that includes two loops (V2 and V3) and forms appropriately only in the oligomeric HIV-1 spike (gp120(3)/gp41(3)). Here we present the crystal structure of 2909 and report structure-function analysis with antibody chimeras composed of 2909 and other members of this antibody class. The 2909 structure was dominated by a heavy-chain third-complementarity-determining region (CDR H3) of 21 residues, which comprised 36% of the combining surface and formed a β-hairpin club extending ∼20 Å beyond the rest of the antibody. Sequence analysis and mass spectrometry identified sites of tyrosine sulfation at the middle and top of CDR H3; substitutions with phenylalanine either ablated (middle substitution) or substantially diminished (top substitution) neutralization. Chimeric antibodies composed of heavy and light chains, exchanged between 2909 and other members of the class, indicated a substantial lack of complementation. Comparison of 2909 to PG16 (which is tyrosine sulfated and the only other member of the class for which a structure has previously been reported) showed that both utilize protruding, anionic CDR H3s for recognition. Thus, despite some diversity, members of this class share structural and functional similarities, with conserved features of the CDR H3 subdomain likely reflecting prevalent solutions by the human immune system for recognition of a quaternary site of HIV-1 vulnerability.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingCrystallography, X-RayHIV-1HIV AntibodiesHumansMass SpectrometryMolecular Sequence DataProtein Structure, QuaternaryRecombinant ProteinsSequence Analysis, DNAAntibodies, MonoclonalAntibodies, NeutralizingHIV AntibodiesRecombinant Proteins

Identifiers

PMID21191009
PMCPMC3067962
OpenAlexW2106228977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.